Bruker Licenses IP from Erasmus Medical Center

Jan 03, 2013

|

NEW YORK (GenomeWeb News) – Bruker today announced it has licensed intellectual property from the Erasmus Medical Center for the rapid testing of beta-lactamase activity using MALDI-TOF technology.

The method being licensed is compatible with the Bruker MALDI Biotyper system, which uses MALDI-TOF mass spectrometry for identifying microorganisms, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

This Week in PLOS

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

Things Not Found

With a new collection, PLOS highlights negative results it has published.

Is the Sequencer Half Full or Half Empty?

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

Packs a Punch

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

Featured White Papers

Reverse Phase Protein Arrays for Cell Signaling: Using the InnoScan 710-IR scanner improves sensitivity and dynamic range.

Infrared detection decreases nitrocellulose autofluorescence and improves RPPA assays signal‐to‐noise ratio over visible wavelength detection

Mar

05

Featured Webinar

Integrating Metabolomic and Proteomic Profiles for 'Less Impersonal' Medicine

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.

Main menu